Explore the words cloud of the DRIVE project. It provides you a very rough idea of what is the project "DRIVE" about.
The following table provides information about the project.
FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA
|Coordinator Country||Spain [ES]|
|Total cost||9˙999˙937 €|
|EC max contribution||8˙999˙812 € (90%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2017-07-01 to 2022-06-30|
Take a look of project's partnership.
|1||FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA||ES (VALENCIA)||coordinator||5˙684˙187.00|
|2||P95 CVBA||BE (LEUVEN)||participant||478˙062.00|
|3||SYNAPSE RESEARCH MANAGEMENT PARTNERS SL||ES (MADRID)||participant||393˙750.00|
|4||ISTITUTO SUPERIORE DI SANITA||IT (ROMA)||participant||382˙500.00|
|5||UNIVERSITA DEGLI STUDI DI FIRENZE||IT (Florence)||participant||350˙812.00|
|6||TERVEYDEN JA HYVINVOINNIN LAITOS||FI (HELSINKI)||participant||349˙250.00|
|7||ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE (IABS-EU)||FR (LYON)||participant||323˙437.00|
|8||UNIVERSITE LYON 1 CLAUDE BERNARD||FR (VILLEURBANNE CEDEX)||participant||315˙250.00|
|9||INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT||FR (MARSEILLE)||participant||303˙687.00|
|10||UNIVERSITY OF SURREY||UK (GUILDFORD)||participant||257˙375.00|
|11||CONFEDERATION OF MENINGITIS ORGANISATIONS LTD||UK (BRISTOL)||participant||161˙500.00|
|12||ABBOTT BIOLOGICALS BV||NL (WEESP)||participant||0.00|
|13||GLAXOSMITHKLINE BIOLOGICALS SA||BE (RIXENSART)||participant||0.00|
|14||SANOFI PASTEUR SA||FR (LYON)||participant||0.00|
|15||SEQIRUS UK LIMITED||UK (MAIDENHEAD)||participant||0.00|
Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the EU. Vaccines are the cornerstone for preventing influenza and its consequences. Current influenza vaccines have a moderate variable effect, given the mismatch between vaccine and circulating strains, waning immunity and interference from previous vaccination, among others.
The single most important challenge in achieving VE studies for the various influenza vaccines put every year on the European market is the ability of the different stakeholders to work in collaboration.
To enable a sustainable network of influenza vaccine VE studies, the Development of Robust and Innovative Vaccines Effectiveness (DRIVE) main goal will be the development of a governance model between public and private entities. This model will ensure scientific independence in the studies and full transparency, allowing different stakeholders to fulfill their needs taking into account their respective obligations and statutes.
A second challenge will be to reach the capacity to perform vaccine brand- specific effectiveness studies, which is agile enough to deliver the needed outputs in timely manner, and robust enough to provide results by different age and risk groups and flexible enough to utilize novel tools while at the same time aims to be sustainable.
Combining these outputs, DRIVE will establish a sustainable platform for joint influenza vaccine effectiveness evaluation which will have a positive impact on European citizens public health.
|Governance Standard Operating Procedures (SOP)||Documents, reports||2020-01-14 14:31:02|
|Web-based survey amongst layer 1 stakeholders||Documents, reports||2019-11-20 12:24:09|
|Report on the Governance SOP implementation||Documents, reports||2019-11-20 12:24:09|
|Report on synergies identified and collaborations developed with other initiatives||Documents, reports||2019-11-20 12:24:09|
|Updated and developed protocol for type- and brand- specific IVES||Documents, reports||2019-11-20 12:24:09|
|Report on feasible novel and innovative approaches for measuring influenza VE||Documents, reports||2019-11-20 12:24:09|
|Report on the collected feed-back from â€œlayer 1â€ [â€¦]||Documents, reports||2019-11-20 12:24:09|
|First seasonal final report of conducted studies||Documents, reports||2019-11-20 12:24:09|
|Updated protocol for type- and brand- specific influenza vaccine effectiveness studies (population-based database studies)||Documents, reports||2019-11-20 12:24:09|
|Communication report of the study milestones arising from WP7 for the use of â€œlayer 1â€ stakeholders||Documents, reports||2019-11-20 12:24:09|
|Annual tender for influenza vaccine effectiveness study conduct||Documents, reports||2019-11-20 12:24:09|
|Methodology guidelines for concerted analysis of data and control of confounding factors||Documents, reports||2019-11-20 12:24:08|
|Points to consider document on the interpretation of VE results||Documents, reports||2019-11-20 12:24:08|
|Project Handbook||Documents, reports||2019-11-20 12:24:08|
|Generic SAP||Documents, reports||2019-11-20 12:24:08|
|IT infrastructure to receive and analyse the data||Websites, patent fillings, videos etc.||2019-11-20 12:24:08|
|Report on the sources for usage of specific influenza vaccine brands and accessibility||Documents, reports||2019-11-20 12:24:08|
|Report with the definition of the ethics policies handbooks collection||Documents, reports||2019-11-20 12:24:08|
|Generic DMP||Documents, reports||2019-11-20 12:24:08|
|Standard Operating Procedures (SOPs) and templates||Documents, reports||2019-11-20 12:24:08|
|Multi Stake-holder Research Agenda||Documents, reports||2019-11-20 12:24:08|
|SWOT analysis plan and list of quality criteria||Documents, reports||2019-11-20 12:24:08|
|Report on the comparison of adapted local protocols and Ethical Committee evaluation in each study site||Documents, reports||2019-11-20 12:24:08|
|Report templates||Documents, reports||2019-11-20 12:24:08|
|Communication of a detailed stakeholder map for the DRIVE project||Documents, reports||2019-11-20 12:24:08|
|Report on the brand availability and usage of specific influenza vaccine brands||Documents, reports||2019-11-20 12:24:08|
|Development of the communications plan||Documents, reports||2019-11-20 12:24:08|
|Guideline for the identification of vaccine status and vaccine used in study participants||Documents, reports||2019-11-20 12:24:09|
|Report of the results of a systematic analysis on existing initiatives, tools, and/or study protocols for determining IVE [â€¦]||Documents, reports||2019-11-20 12:24:09|
|Electronic study support application||Websites, patent fillings, videos etc.||2019-11-20 12:24:09|
|Evaluation reports of how the vaccine effectiveness results could fulfil the new regulatory requirements||Documents, reports||2019-11-20 12:24:09|
|Written report on quality and feasibility evaluation||Documents, reports||2019-11-20 12:24:09|
|Agreement on communications governance model||Documents, reports||2019-11-20 12:24:09|
|Tailored, timely seasonal summaries of VE results for different stakeholder/clients in layer 1 and 2||Documents, reports||2019-11-20 12:24:09|
|Periodical back-to-back Forum of key stakeholders [â€¦]||Documents, reports||2019-11-20 12:24:09|
Take a look to the deliverables list in detail: detailed list of DRIVE deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DRIVE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DRIVE" are provided by the European Opendata Portal: CORDIS opendata.
Antibiotic Distribution and Recovery in TissueRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitorsRead More